AZZ Inc: Form 10-Q for the period ended Nov 30, 2022
Filed with the SEC on Jan 9, 2023 and accepted by EDGAR at Jan 9, 2023, 16:30 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-11-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-09-01 to 2022-11-30 | $373.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2022-03-01 to 2022-11-30 | $987.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2022-09-01 to 2022-11-30 | $300.2m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2022-03-01 to 2022-11-30 | $752.5m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2022-09-01 to 2022-11-30 | $73.1m | us-gaap:GrossProfit |
| Gross profit | 9 months2022-03-01 to 2022-11-30 | $234.7m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2022-09-01 to 2022-11-30 | $27.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2022-03-01 to 2022-11-30 | $97.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2022-09-01 to 2022-11-30 | $45.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2022-03-01 to 2022-11-30 | $137.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-09-01 to 2022-11-30 | $26.1m | us-gaap:InterestExpense |
| Interest expense | 9 months2022-03-01 to 2022-11-30 | $61.7m | us-gaap:InterestExpense |
| Income tax | 3 months2022-09-01 to 2022-11-30 | $2.4m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2022-03-01 to 2022-11-30 | $18.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-09-01 to 2022-11-30 | −$20.5m | us-gaap:NetIncomeLoss |
| Net income | 9 months2022-03-01 to 2022-11-30 | −$54.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-09-01 to 2022-11-30 | −$0.97 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2022-03-01 to 2022-11-30 | −$2.35 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-09-01 to 2022-11-30 | −$0.97 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2022-03-01 to 2022-11-30 | −$2.37 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-09-01 to 2022-11-30 | 24,995,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2022-03-01 to 2022-11-30 | 24,984,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2022-03-01 to 2022-11-30 | $68.6m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 9 months2022-03-01 to 2022-11-30 | $35.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months2022-03-01 to 2022-11-30 | $12.7m | us-gaap:PaymentsOfDividends |
| Share repurchases | 9 months2022-03-01 to 2022-11-30 | $0 | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2022-11-30 | $3.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-11-30 | $406.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-11-30 | $2.20bn | us-gaap:Assets |
| Current liabilities | At period end2022-11-30 | $220.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-11-30 | $1.35bn | us-gaap:Liabilities |
| Long-term debt | At period end2022-11-30 | $1.01bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2022-11-30 | $13.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2022-11-30 | $852.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000008947-23-000012. Last ingested by Listed: Oct 26, 2026, 16:17 ET. Listed shows no prices and gives no investment advice.